home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  June 17, 2024
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 462 active entries


Am Klopferspitz 19a
Martinsried/Munich, 82152

Phone: +49-(0)89- 780 16 65-0
Fax: +49-(0)89- 780 16 65 -11


Leukocare AG is the leading innovator for drug product development and analytical services of small molecule parenterals and biologics such as proteins, viruses, viral vectors, exosomes, mRNA, and many more. Leukocare’s unique technology provides clients with superior stabilization and optimal formulation of drug products tailored to the target product profile. This reduces risks and time in drug development programs and can significantly increase commercial success. These services can also support life-cycle management of already commercialized products.

Due to the combination of in-silico tools and wet lab experiments, a very large number of excipient combinations can be explored, without needing large amounts of drug substance and development time. For this approach, Leukocare developed its own software tools and algorithms, which follow quality by design principles. To reduce hurdles on the way to the clinic, Leukocare uses only excipients with regulatory approval for the intended route of administration.

In addition to formulation development services, Leukocare offers the ability to extend the scientific workbench of clients by providing analytical and bioinformatic services for drug discovery and development projects. This robust analytical expertise is applied to services ranging from developability assessment, particle characterization, stability and molecular integrity analysis, long-term stability prediction, molecular modeling to support candidate selection of drug substances, and non-GMP filling for toxicology studies.

Selected Categories:
Product Company   Service Company
- Research
- Services

Last update of this entry: October 09, 2023

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.